T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Weyerhaeuser
WY
$18B
| $1.45B | 0.31% |
43,734,245
+788,866
| +2% | +$23.8M |
|
|
LNKD
77
DELISTED
LinkedIn Corporation
LNKD
| $1.43B | 0.31% |
8,353,536
+833,850
| +11% | +$135M |
|
78
AT&T
T
$167B
| $1.43B | 0.31% |
53,611,170
-5,639,334
| -10% | -$151M |
|
|
APC
79
DELISTED
Anadarko Petroleum
APC
| $1.42B | 0.31% |
12,993,016
-593,023
| -4% | -$60.4M |
|
80
Trip.com Group
TCOM
$29.1B
| $1.42B | 0.31% |
44,242,034
-521,682
| -1% | -$14.1M |
|
81
O'Reilly Automotive
ORLY
$75B
| $1.41B | 0.3% |
140,083,320
-14,741,790
| -10% | -$145M |
|
|
HES
82
DELISTED
Hess
HES
| $1.39B | 0.3% |
14,019,762
+427,462
| +3% | +$38.6M |
|
83
NRG Energy
NRG
$25.3B
| $1.38B | 0.3% |
37,218,358
-769,249
| -2% | -$26.5M |
|
84
Invesco
IVZ
$13.9B
| $1.37B | 0.3% |
36,225,570
+1,320,324
| +4% | +$47.8M |
|
85
Celanese
CE
$4.93B
| $1.35B | 0.29% |
21,015,228
-1,621,140
| -7% | -$98.4M |
|
86
Aptiv
APTV
$10.3B
| $1.32B | 0.29% |
19,255,230
+216,736
| +1% | +$14.7M |
|
87
Verizon
VZ
$196B
| $1.32B | 0.28% |
26,942,143
-3,382,185
| -11% | -$164M |
|
88
Vertex Pharmaceuticals
VRTX
$134B
| $1.31B | 0.28% |
13,866,784
+2,041,774
| +17% | +$143M |
|
89
Textron
TXT
$15.2B
| $1.31B | 0.28% |
34,214,295
+2,773,291
| +9% | +$109M |
|
|
KSU
90
DELISTED
Kansas City Southern
KSU
| $1.28B | 0.28% |
11,908,763
-1,342,340
| -10% | -$139M |
|
91
Qualcomm
QCOM
$171B
| $1.28B | 0.28% |
16,102,728
-4,992,540
| -24% | -$397M |
|
92
Citigroup
C
$228B
| $1.23B | 0.27% |
26,145,945
+1,291,380
| +5% | +$61.4M |
|
93
United Airlines
UAL
$41.1B
| $1.21B | 0.26% |
29,506,234
-10,626,243
| -26% | -$458M |
|
94
Dollar Tree
DLTR
$24.5B
| $1.19B | 0.26% |
21,791,600
-1,661,854
| -7% | -$87.4M |
|
95
Incyte
INCY
$24.5B
| $1.19B | 0.26% |
21,006,208
-1,316,008
| -6% | -$67.2M |
|
96
Humana
HUM
$45.1B
| $1.18B | 0.25% |
9,222,120
+2,516,575
| +38% | +$298M |
|
|
HSP
97
DELISTED
HOSPIRA INC
HSP
| $1.17B | 0.25% |
22,842,928
+4,104,974
| +22% | +$195M |
|
98
Applied Materials
AMAT
$416B
| $1.17B | 0.25% |
51,919,502
-3,004,249
| -5% | -$61.3M |
|
99
Entergy
ETR
$49.7B
| $1.16B | 0.25% |
28,319,744
-11,570,428
| -29% | -$432M |
|
100
FedEx
FDX
$76.1B
| $1.13B | 0.24% |
7,437,420
-2,804,899
| -27% | -$392M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.